Production of a High-affinity Monoclonal Antibody Reactive with XXXX Receptors Alpha and Beta.

@entity1501 @entity1 @entity137 @entity573 @entity5 @entity5434 @entity2 @entity7533 @entity3689 @entity309
UNASSIGNED: Folate receptors a (FRa) and b (FRb) are two isoforms of the cell surface glycoprotein that binds @entity1501 . The expression of FRa is rare in normal cells and elevated in @entity5 cells. Thus, FRa-based @entity5 -targeted therapy has been a focus area of laboratory research and clinical trials. Recently, it was shown that a significant fraction of @entity5 -associated macrophages expresses FRb and that these cells can enhance @entity5 growth. Although FRa and FRb share 70% identity in their deduced @entity3689 sequence, a monoclonal antibody (MAb) reactive with both receptors has not been developed. A MAb that can target both FRa-expressing @entity5 cells and FRb-expressing @entity5 -associated macrophages may provide a more potent therapeutic tool for @entity5 than individual anti-FRa or anti-FRb MAbs. In this study, we developed a MAb that recognizes both FRa and FRb (anti-FRab). The anti-FRab specifically stained trophoblasts and macrophages from @entity1 placenta, synovial macrophages from @entity309 @entity1 , liver macrophages from @entity5434 and @entity7533 , and @entity5 cells and @entity5 -associated macrophages from @entity2 . Surface plasmon resonance showed that the anti-FRab bound to soluble forms of the FRa and FRb proteins with high affinity ( @entity573 =6.26*10(-9)   M and 4.33*10(-9)   M, respectively). In vitro functional analysis of the anti-FRab showed that this MAb mediates complement-dependent @entity137 , antibody-dependent cellular @entity137 , and antibody-dependent cellular phagocytosis of FRa-expressing and FRb-expressing cell lines. The anti-FRab MAb is a promising therapeutic candidate for @entity5 in which macrophages promote @entity5 progression.
